Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

raloxifene hydrochloride

(ra-LOK-sih-feen HY-droh-KLOR-ide)
A drug used to reduce the risk of invasive breast cancer in postmenopausal women who are at high risk of developing the disease or who have osteoporosis and to prevent and treat osteoporosis in postmenopausal women. Raloxifene hydrochloride is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in breast tissue, which may help keep breast cancer cells from growing. Raloxifene hydrochloride may also help keep bone from breaking down. It is a type of selective estrogen receptor modulator (SERM). Raloxifene is the active ingredient of raloxifene hydrochloride. Also called Evista.
More Information
Search NCI's Dictionary of Cancer Terms